Medicare Part D Choices Decline as Coverage Options Shrink

Medicare beneficiaries face a reduction in prescription drug coverage options this fall, continuing a trend that has persisted for several years. As the open enrollment period approaches, patients will find fewer standalone drug plans available for 2026, with many options becoming particularly limited for those qualifying for low-income subsidies. Shoppers have from October 15 to December 7 to select new coverage that will take effect in January.

The available choices for standalone Medicare Part D plans have decreased significantly. According to the non-profit KFF, approximately 23 million individuals with regular Medicare currently utilize standalone coverage. In contrast, around 34 million people have Medicare Advantage plans, which often include prescription coverage. In 2026, typical shoppers will have access to between eight and twelve standalone drug plans, down from twelve to sixteen options in 2025. Just five years ago, choices were nearly double, with almost 30 options available in 2021.

Market Dynamics and Financial Pressures

The contraction in available plans is primarily due to insurers pulling back from the market. Notably, the Blue Cross-Blue Shield carrier Elevance has announced its exit from standalone Part D plans entirely. The Inflation Reduction Act, which will cap annual out-of-pocket drug costs at $2,100 starting in 2026, has added financial pressures on insurers, making it less attractive for them to provide plans. This legislation also allows patients to spread their prescription costs evenly throughout the year.

Many beneficiaries are hesitant to shop for new plans, especially if they already have a plan that meets their needs. Juliette Cubanski, a Medicare expert at KFF, pointed out that beneficiaries often feel a sense of inertia, fearing that switching plans may lead to worse outcomes. This reluctance is evident as nearly 11% of those with standalone coverage lost their plans in 2024, a sharp increase from figures that typically hovered below 1% before 2023, according to research published in the Journal of the American Medical Association.

Cost Trends and Consumer Guidance

The Centers for Medicare and Medicaid Services recently announced that average monthly premiums for Part D plans are expected to decline by nearly 10%, bringing the average to $34.50. Many regions will offer at least one plan with a premium under $20. Despite these lower premiums, beneficiaries should remain vigilant, as some plans may increase deductibles or limit the list of covered medications, known as formularies.

Insurers will have the ability to raise premiums by as much as $50 per month for 2026, an increase from the $35 allowed in the previous year. Nevertheless, not all plans will reach this upper limit, and the impact will vary by state.

For those navigating the enrollment process, resources are available to assist in comparing plans. A federal government website can help beneficiaries evaluate plan prices and coverage. Each state has a dedicated State Health Insurance Program designed to aid individuals on Medicare in finding suitable coverage. Consumers are advised to review their current plans for any changes and to consider whether their preferred pharmacy is included in the networks of potential new plans.

As the enrollment window progresses, experts note that many individuals wait until the final days to make decisions, often postponing until family discussions during holiday gatherings. This behavior can lead to a last-minute rush that complicates the search for suitable coverage.

The current landscape for Medicare Part D indicates a challenging environment for beneficiaries seeking prescription drug coverage. With fewer options and increased financial pressures on insurers, it is crucial for individuals to actively assess their needs and explore available plans before the enrollment period closes.